ClinicalTrials.gg
RecruitingNCT07391995MINI-OSUpdated Nov 13, 2026

New Diagnostic Tool (MinION) for Identifying Microorganisms in Foot Wounds of Patients Living With Diabetic Foot Osteomyelitis

An observational study in Diabetes Mellitus, Diabetes Complications and Diabetic Peripheral Neuropathy, sponsored by Centre Hospitalier Universitaire de Nīmes. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2026-11-13.

Primary conditionDiabetic FootRegistry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetic Foot
Why
  1. The study's title name Diabetic Foot, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre Hospitalier Universitaire de Nīmes · Observational

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 13, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
43
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes — 3 open to participants now, 3 under way, none of them phase 3. Diabetic Foot · Centre Hospitalier Universitaire de Nīmes.

Started
2026
with 1 other
Observational
6 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 10th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

3 of the 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 139 Diabetic Foot studies recruiting now, 98 (71%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetic Foot by Centre Hospitalier Universitaire de Nīmes, or all of them as a file.
02

Study summary

Diabetic foot wound infections are predominantly polymicrobial. However, 'conventional' microbiological culture does not identify all the bacteria potentially involved in these infections and requires time, which can have a negative impact by delaying treatment and/or the prescription of appropriate antibiotic therapy.

Real-time metagenomics analysis using Oxford Nanopore Technologies' MinION technology has demonstrated sufficient power to identify virtually all microbial genomes in a given sample, providing additional information on their antibiotic resistance profile and in silico prediction of genes encoding virulence factors within than 4 hours. Based on these rapid results, a management protocol could be defined specifically for each patient with a view to personalised medicine.

The aim is to study the diversity of bacterial and fungal species identified using the MinION method and compare this diversity with the results obtained using conventional methods (routine culture) from bone biopsies taken from DFOM patients.

Read the detailed description

Diabetes mellitus is one of the most common diseases in the world. Among its complications, 34% of patients living with diabetes will develop foot ulcers during their lifetime. Once this lesion has developed due to triopathy (arteriopathy, neuropathy, immunopathy), over 50% of these wounds will become infected, leading to serious consequences: bone damage (60 to 80% of cases), amputation (20% of infected wounds), mortality (68% at 5 years) and morbidity. The additional costs associated with this condition exceed $850 billion worldwide, with $1 million spent every 30 seconds due to complications from these wounds in the US. Diabetic foot ulcers (DFUs) are therefore a major public health problem.

For infectious disease specialists, one of the main difficulties in treating infections in these wounds is distinguishing between bacterial colonization - a physiological process, and infection - a pathological process. Studies of the microbiota of foot wounds in diabetic patients show the polymicrobial nature of these lesions, which contain commensal bacteria from the skin microbiota, opportunistic pathogenic bacteria and bacteria from the environment. Among Gram-positive cocci, Staphylococcus aureus is the species most often identified in diabetic foot osteomyelitis (DFO) (23.4%), followed by Pseudomonas spp. (11.1%), Escherichia coli (11.5%), Proteus spp. (8.3%), Klebsiella spp. (6.9%), and Enterococcus spp. (5.4%). Coagulase-negative staphylococci, although involved in less than 4% of infections, often remain difficult to identify by mass spectrometry at species level, even though some of them are known for their pathogenicity. The other major difficulty is the time it takes to obtain results when osteomyelitis is suspected. In such situations, obtaining a bone sample is the standard method and the best way to identify the pathogen(s) responsible and their sensitivity to antibiotics. Bone biopsy can be performed intraoperatively or percutaneously, as recommended by the International Working Group of the Diabetic Foot (IWGDF) in 2023. In addition, to avoid false-negative cultures, experts suggest delaying bone biopsy in patients already on antibiotics, ideally for at least two weeks. In the microbiology laboratory, the standard diagnosis based on conventional microbiological culture can take up to two weeks to identify the causative bacteria and perform antibiotic susceptibility testing on the responsible pathogen(s), bringing the total time to establish a diagnosis to 4 weeks.To reduce this delay, certain culture-free molecular microbiology techniques, in particular metagenomic next-generation sequencing (mNGS), have shown that the microbiota of most wound infections is more diverse and abundant than that revealed by conventional culture methods. However, very few metagenomic data on bone biopsies from DFOMs are available. As molecular biology tools were unable to distinguish between live and dead bacterial cells and cannot identify the bacterial genera contributing to the clinical status of the infection, their use in daily practice is not recommended by the IWGDF and SPILF (Société de Pathologie Infectieuse de Langue Française), as their results could lead to the unnecessary use of broad-spectrum antibiotics. Recent studies based on metagenomic analysis of bone biopsies, soft tissue biopsies and swabs from foot wounds in diabetic patients have identified microbial diversity as a marker of infection. The number of bacteria involved in confirmed cases of infection is estimated at over 70, a figure difficult to achieve with conventional routine methods. The use of PCR based on amplification of the gene coding for 16S rRNA is considered unsuitable due to the frequent polymicrobial nature of DFOM samples. Multiplex PCR methods are not exhaustive in identifying all pathogens. Finally, conventional culture methods are often time-consuming, and species identification using laboratory methods such as MALDI-TOF mass spectrometry is often a source of confusion or failure. Recently, a new rapid sequencing tool has been developed: the MinION. It is small and fast and can sequence a bacterial or viral genome from single-microbe samples in less than four hours, or determine a panel of microorganisms present in a more complex sample. This tool is particularly useful for cerebrospinal fluid.

03

Conditions studied

  • Diabetes Mellitus
  • Diabetes Complications
  • Diabetic Peripheral Neuropathy

Browse trials for

Keywords

  • Foot Ulcer, Diabetic
  • Infection
04

In context

Diabetic Foot Reclassified

1,079 studies on the registry are indexed under Diabetic Foot; 221 are open to participants now.

This study's planned enrollment of 43 is below the median of 100 across 191 observational studies indexed under Diabetic Foot.

Browse Diabetic Foot studies →

Lead sponsor

Centre Hospitalier Universitaire de Nīmes is the lead sponsor of 595 studies on the registry; 87 are open to participants now.

Compared within Diabetic Foot, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

147 bone biopsies from 43 diabetic patients collected in the orthopedic surgery operating room

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • N/A

Exclusion criteria

Exclusion Criteria:

  • N/A
06

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
43 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
07

What researchers measure

Primary outcomes

  1. Number of bacterial and fungal species found in a conventional bone biopsy

    Number of species found by each method (presence/absence and species identification): bacterial and fungal species detected in bone biopsies by the two methods (conventional culture vs MinION

    Time frame: 12 months

  2. Number of bacterial and fungal species found with the MiniON device

    Number of species found by each method (presence/absence and species identification): bacterial and fungal species detected in bone biopsies by the two methods (conventional culture vs MinION

    Time frame: 12 months

Secondary outcomes

  1. Description of the bone microbiota of diabetic foot osteomyelitis using the MinION method

    Typology of microbial species found using the MinION method. The MinION™ Mk1D is the next generation of portable nanopore sequencing devices. Improved thermal dissipation capabilities of the MinION Mk1D significantly enhances sequencing performance, enabling highly accurate real-time sequencing in an even wider range of environments than its predecessor, the MinION Mk1B.

    Time frame: 12 months

  2. Description of the bone microbiota of diabetic foot osteomyelitis using the conventional method (MALDI-TOF)

    Typology of microbial species found using the MALDI-TOF method. The MALDI-TOF (Matrix Assisted Laser Desorption Ionization - Time of Flight) instrument is a mass spectrometer that combines a matrix-assisted laser ionization source (MALDI) with a time-of-flight analyzer (TOF). One of the important characteristics of mass spectrometry is peak sharpness, measured by the resolution of the mass spectrometer. Resolution is defined as the ratio of the peak mass m to the full width at half maximum Δm. The higher the resolution, the sharper the peaks. This makes it possible to visualize two molecules with similar masses. MALDI-TOF instruments can be equipped with a reflection (electrostatic mirror or "ion mirror") that deflects ions with an electric field, thereby doubling the length of the ion flight path and increasing the resolution of the instrument. A MALDI-TOF mass spectrometer can achieve resolutions of 5000 in linear mode (without reflection) and 20000 with reflecton.

    Time frame: 12 months

  3. New potentially pathogenic species in diabetic foot osteomyelitis in relation to wound progression.

    Degree of wound healing at 3 months, 6 months and one year, depending on the presence or absence of different microbial species.

    Time frame: 3 months

  4. New potentially pathogenic species in diabetic foot osteomyelitis in relation to wound progression.

    Degree of wound healing at 3 months, 6 months and one year, depending on the presence or absence of different microbial species.

    Time frame: 6 months

  5. New potentially pathogenic species in diabetic foot osteomyelitis in relation to wound progression.

    Degree of wound healing at 3 months, 6 months and one year, depending on the presence or absence of different microbial species.

    Time frame: 12 months

  6. Antibiotic sensitivity profiles of microorganisms obtained in vitro (bacterial culture).

    The number and % of strains resistant to antibiotics tested on pathogenic bacteria isolated in standard microbiological culture will be recorded.

    Time frame: 12 months

  7. Antibiotic sensitivity profiles of microorganisms obtained in silico (MinION technology).

    Presence/absence of resistance genes to the antibiotic families tested on pathogenic bacteria isolated in standard microbiological culture

    Time frame: 12 months

  8. Cost of conventional in vitro culture and testing

    Cost in Euros

    Time frame: 12 months

  9. Cost of using in silico MinION technology

    Cost in Euros

    Time frame: 12 months

Other outcomes

  1. Gender of patients providing samples

    Male/female/Non-binary

    Time frame: Baseline

  2. Age of patients providing samples

    In years

    Time frame: Baseline

  3. Body mass index of patients providing samples

    The formula is BMI = kg/m2; kg is a person's weight in kilograms and m2 is height in meters squared

    Time frame: Baseline

  4. Wound grade

    Wagner Grade 1: Partial- or full-thickness ulcer (superficial ulcer) Wagner Grade 2: Deep ulcer extended to ligament, tendon, joint capsule, bone, or deep fascia without abscess or osteomyelitis (OM) Wagner Grade 3: Deep abscess, OM, or joint sepsis. Wagner Grade 4: Partial-foot gangrene.

    Time frame: Baseline

  5. Previous antibiotherapy

    YES/NO

    Time frame: Baseline

  6. Evolution of the wound at 3 months

    Healed/Worsening

    Time frame: Month 3

  7. Evolution of the wound at 6 months

    Healed/Worsening

    Time frame: Month 6

  8. Evolution of the wound at 12 months

    Healed/Worsening

    Time frame: Month 12

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Lipsky BA, Senneville E, Abbas ZG, Aragon-Sanchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbancic-Rovan V, Peters EJG; International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280. doi: 10.1002/dmrr.3280. PubMed 32176444 ↗
  • Cascini S, Agabiti N, Davoli M, Uccioli L, Meloni M, Giurato L, Marino C, Bargagli AM. Survival and factors predicting mortality after major and minor lower-extremity amputations among patients with diabetes: a population-based study using health information systems. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001355. doi: 10.1136/bmjdrc-2020-001355. PubMed 32690575 ↗
  • Armstrong DG, Kanda VA, Lavery LA, Marston W, Mills JL Sr, Boulton AJ. Mind the gap: disparity between research funding and costs of care for diabetic foot ulcers. Diabetes Care. 2013 Jul;36(7):1815-7. doi: 10.2337/dc12-2285. No abstract available. PubMed 23801792 ↗
  • Radzieta M, Sadeghpour-Heravi F, Peters TJ, Hu H, Vickery K, Jeffries T, Dickson HG, Schwarzer S, Jensen SO, Malone M. A multiomics approach to identify host-microbe alterations associated with infection severity in diabetic foot infections: a pilot study. NPJ Biofilms Microbiomes. 2021 Mar 22;7(1):29. doi: 10.1038/s41522-021-00202-x. PubMed 33753735 ↗
  • Jneid J, Cassir N, Schuldiner S, Jourdan N, Sotto A, Lavigne JP, La Scola B. Exploring the Microbiota of Diabetic Foot Infections With Culturomics. Front Cell Infect Microbiol. 2018 Aug 14;8:282. doi: 10.3389/fcimb.2018.00282. eCollection 2018. PubMed 30155447 ↗
  • Macdonald KE, Boeckh S, Stacey HJ, Jones JD. The microbiology of diabetic foot infections: a meta-analysis. BMC Infect Dis. 2021 Aug 9;21(1):770. doi: 10.1186/s12879-021-06516-7. PubMed 34372789 ↗
  • Manas AB, Taori S, Ahluwalia R, Slim H, Manu C, Rashid H, Kavarthapu V, Edmonds M, Vas PRJ. Admission Time Deep Swab Specimens Compared With Surgical Bone Sampling in Hospitalized Individuals With Diabetic Foot Osteomyelitis and Soft Tissue Infection. Int J Low Extrem Wounds. 2021 Dec;20(4):300-308. doi: 10.1177/1534734620916386. Epub 2020 May 5. PubMed 32370639 ↗
  • Macauley M, Adams G, Mackenny P, Kubelka I, Scott E, Buckworth R, Biddiscombe C, Aitkins C, Lake H, Matthews V, Ashraff S, Ashwell S. Microbiological evaluation of resection margins of the infected diabetic foot ulcer. Diabet Med. 2021 Apr;38(4):e14440. doi: 10.1111/dme.14440. Epub 2020 Nov 11. PubMed 33113230 ↗
  • Senneville E, Albalawi Z, van Asten SA, Abbas ZG, Allison G, Aragon-Sanchez J, Embil JM, Lavery LA, Alhasan M, Oz O, Uckay I, Urbancic-Rovan V, Xu ZR, Peters EJG. IWGDF/IDSA guidelines on the diagnosis and treatment of diabetes-related foot infections (IWGDF/IDSA 2023). Diabetes Metab Res Rev. 2024 Mar;40(3):e3687. doi: 10.1002/dmrr.3687. Epub 2023 Oct 1. PubMed 37779323 ↗
  • Chen Y, Shi Y, Zhu W, You J, Yang J, Xie Y, Zhao H, Li H, Fan S, Li L, Liu C. Combining CRISPR-Cas12a-Based Technology and Metagenomics Next Generation Sequencing: A New Paradigm for Rapid and Full-Scale Detection of Microbes in Infectious Diabetic Foot Samples. Front Microbiol. 2021 Oct 7;12:742040. doi: 10.3389/fmicb.2021.742040. eCollection 2021. PubMed 34690988 ↗
  • Malone M, Johani K, Jensen SO, Gosbell IB, Dickson HG, Hu H, Vickery K. Next Generation DNA Sequencing of Tissues from Infected Diabetic Foot Ulcers. EBioMedicine. 2017 Jul;21:142-149. doi: 10.1016/j.ebiom.2017.06.026. Epub 2017 Jun 27. PubMed 28669650 ↗
  • Morsli M, Salipante F, Magnan C, Dunyach-Remy C, Sotto A, Lavigne JP. Direct metagenomics investigation of non-surgical hard-to-heal wounds: a review. Ann Clin Microbiol Antimicrob. 2024 May 3;23(1):39. doi: 10.1186/s12941-024-00698-z. PubMed 38702796 ↗
  • Eshaghi A, Bommersbach C, Zittermann S, Burnham CA, Patel R, Schuetz AN, Patel SN, Kus JV. Phenotypic and Genomic Profiling of Staphylococcus argenteus in Canada and the United States and Recommendations for Clinical Result Reporting. J Clin Microbiol. 2021 May 19;59(6):e02470-20. doi: 10.1128/JCM.02470-20. Print 2021 May 19. PubMed 33731414 ↗
  • Morsli M, Bechah Y, Coulibaly O, Toro A, Fournier PE, Houhamdi L, Drancourt M. Direct diagnosis of Pasteurella multocida meningitis using next-generation sequencing. Lancet Microbe. 2022 Jan;3(1):e6. doi: 10.1016/S2666-5247(21)00277-9. Epub 2021 Nov 11. No abstract available. PubMed 35544115 ↗
  • Morsli M, Kerharo Q, Amrane S, Parola P, Fournier PE, Drancourt M. Real-time whole genome sequencing direct diagnosis of Streptococcus pneumoniae meningitis: A case report. J Infect. 2021 Dec;83(6):709-737. doi: 10.1016/j.jinf.2021.10.002. Epub 2021 Oct 8. No abstract available. PubMed 34627841 ↗
  • Morsli M, Boudet A, Kerharo Q, Stephan R, Salipante F, Dunyach-Remy C, Houhamdi L, Fournier PE, Lavigne JP, Drancourt M. Real-time metagenomics-based diagnosis of community-acquired meningitis: A prospective series, southern France. EBioMedicine. 2022 Oct;84:104247. doi: 10.1016/j.ebiom.2022.104247. Epub 2022 Sep 7. PubMed 36087524 ↗
10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Feb 2026 (actual). Primary completion is estimated for Jun 2027, 16 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jan 2026 → Feb 2026, primary completion Jun 2026 → Jun 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2026
First posted
Feb 6, 2026
StartActual
Feb 12, 2026was Jan 2026
Primary completionEst.
Jun 2027was Jun 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jan 1, 2026→Feb 12, 2026
Nov 13, 2026
Primary completion
Jun 2026→Jun 2027
Nov 13, 2026
Study completion
Dec 2026→Dec 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Start date Jan 1, 2026→Feb 12, 2026
    Primary completion Jun 2026→Jun 2027
    Study completion Dec 2026→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07391995
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Feb 12, 2026
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Madjid MORSLI, Dr.
Contact
madjid.morsli@chu-nimes.fr
+334 66 68 31 17
Anissa MEGZARI
Contact
drc@chu-nimes.fr
0466684236
Adeline Dubois, Dr.
principal investigator · Nîmes University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion